Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 9:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2593–2616 of 5,329 matching trials from the live ClinicalTrials.gov search.
Conditions
Solid Tumors
Interventions
OPB-111077
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Lupus Erythematosus, Systemic
Interventions
Placebo, Belimumab 1 mg/kg, Belimumab 4 mg/kg, Belimumab 10 mg/kg
Drug
Lead sponsor
Human Genome Sciences Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
60
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 52 more
Conditions
Myelodysplastic Syndrome
Interventions
AR-67 (20S)-7-t-Butyldimethylsilyl-10-hydroxycamptothecin)
Drug
Lead sponsor
Arno Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Houston, Texas
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Elsubrutinib, Placebo for Elsubrutinib, Upadacitinib, Placebo for Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
21
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Alamitos, California + 18 more
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions
Binimetinib, Docetaxel, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
MK-1092, 4.0 nmol/kg, MK-1092, 8.0 nmol/kg, MK-1092, 16 nmol/kg, MK-1092, 32 nmol/kg, MK-1092, 64 nmol/kg, Glargine 3.0 nmol/kg, Lispro 1.2 nmol/kg, Placebo to glargine, Placebo to MK-1092, Dextrose, Insulin
Drug · Other · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chula Vista, California
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Carfilzomib, Dexamethasone, Lenalidomide (Control)
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Detroit, Michigan
Conditions
Advanced Non-hematologic Malignancies, Advanced Metastatic Melanoma
Interventions
TAK-733
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Detriot, Michigan • Buffalo, New York
Conditions
Diabetes Mellitus, Type 1, Diabetes Complications
Interventions
Device specific training, Study clinician/educator visit
Device · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • The Bronx, New York
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Misoprostol Ripening Efficacy With Dilapan

NCT03670836
Conditions
Labor Onset and Length Abnormalities, Induced; Birth
Interventions
Dilapan, Misoprostol
Device · Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
307 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
2
States / cities
New York, New York • Galveston, Texas
Conditions
Pain, Neoplasm, Cancer
Interventions
Tapentadol in the Titration Phase, Morphine in the Maintenance Phase, Matching Placebo in the Maintenance Phase after Tapentadol in the Titration Phase, Tapentadol in the Maintenance Phase, Morphine in the Titration Phase
Drug
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
7
States / cities
St. Petersburg, Florida • Elkhart, Indiana • Shreveport, Louisiana + 4 more
Conditions
Pulmonary Arterial Hypertension
Interventions
QCC374
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Neuroendocrine Carcinoma, Neuroendocrine Tumors
Interventions
Seneca Valley Virus-001 (SVV-001), Nivolumab, Ipilimumab
Biological · Drug
Lead sponsor
Peter Hosein, MD
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Miami, Florida
Conditions
Relapsed Refractory Multiple Myeloma (RRMM)
Interventions
Talquetamab, Mezigdomide, Dexamethasone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Age Comparisons of Exercising Muscle O2 Supply in Healthy Adults: Effects of Esmolol Infusion

NCT04181606
Conditions
Aging
Interventions
Esmolol infusion, Saline infusion, Pre exercise baseline, Isometric handgrip exercise, Semi-recumbent cycling
Drug · Other
Lead sponsor
David N. Proctor, PhD
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
University Park, Pennsylvania
Terminated Phase 2Phase 3 Interventional Results available

Nintedanib (BIBF 1120) in Mesothelioma

NCT01907100
Conditions
Mesothelioma
Interventions
Nintedanib, Pemetrexed, Cisplatin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
10
States / cities
Birmingham, Alabama • San Francisco, California • Littleton, Colorado + 7 more
Conditions
Recurrent Group 3 Medulloblastoma, Recurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma
Interventions
TTRNA-DC vaccines with GM-CSF, TTRNA-xALT, Td vaccine, autologous HSCs, Pembrolizumab
Biological · Drug
Lead sponsor
University of Florida
Other
Eligibility
4 Years to 30 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Gainesville, Florida
Conditions
Sickle Cell Disease
Interventions
Busulfan, Fludarabine, r-ATG, Hematopoietic Cell Transplant, Tacrolimus, Methotrexate, Standard of Care, Alemtuzumab, Total Body Irradiation (TBI), Sirolimus, Melphalan, G-CSF
Drug · Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
15 Years to 40 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
35
States / cities
Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 25 more
Conditions
Neuroendocrine Tumors, Gastrointestinal Neoplasms, Carcinoid Tumors
Interventions
Lanreotide, Y-90 microspheres
Drug · Device
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
3
States / cities
Denver, Colorado • Kansas City, Missouri • Nashville, Tennessee
Conditions
Stroke, Ischemic, Stroke Hemorrhagic, Stroke, Cerebrovascular
Interventions
Reactive balance training with Neuromuscular Electrical Stimulation, Reactive balance training without Neuromuscular Electrical Stimulation
Behavioral
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years to 90 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Completed Phase 3 Interventional Results available

Methotrexate and Mycophenolate Mofetil for UVEITIS

NCT01829295
Conditions
Uveitis
Interventions
Mycophenolate mofetil, Methotrexate, Prednisone
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
16 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Portland, Oregon
Conditions
Postpartum Depression
Interventions
ZULRESSO®
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Culver City, California • Miramar, Florida • Pompano Beach, Florida + 2 more
Conditions
Systemic Juvenile Idiopathic Arthritis With Active Flare
Interventions
canakinumab, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 19 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
12
States / cities
Little Rock, Arkansas • Washington D.C., District of Columbia • Chicago, Illinois + 6 more
Conditions
Premature Birth
Interventions
Tummy time and parent education, Parent education only
Behavioral
Lead sponsor
University of Indianapolis
Other
Eligibility
35 Weeks to 44 Weeks
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chicago, Illinois